We are live on ! Find out more
MB

MPM BioImpact Portfolio holdings

AUM $1.64B
1-Year Est. Return 245.64%
This Fund
S&P 500
This Quarter Est. Return
+18.1%
1 Year Est. Return
+245.64%
3 Year Est. Return
+550.3%
5 Year Est. Return
+647.56%
10 Year Est. Return
–
AUM
$422M
AUM Growth
+$62.2M
Cap. Flow
+$55.4M
Cap. Flow %
13.12%
Top 10 Hldgs %
68.75%
Holding
41
New
4
Increased
4
Reduced
14
Closed
3

Top Buys

Rank Stock Value
1
VERV
Verve Therapeutics
VERV
+$20.3M
2
RGNX icon
Regenxbio
RGNX
+$18.4M
3
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$13.8M
4
IOVA icon
Iovance Biotherapeutics
IOVA
+$5.77M
5
NTLA icon
Intellia Therapeutics
NTLA
+$4.65M

Top Sells

Rank Stock Value
1
EPZM
Epizyme, Inc
EPZM
+$5.04M
2
MIRM icon
Mirum Pharmaceuticals
MIRM
+$4.6M
3
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$2.53M
4
FOLD
Amicus Therapeutics
FOLD
+$1.14M
5
NEO icon
NeoGenomics
NEO
+$1.1M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CGEM icon
1
Cullinan Oncology
CGEM
$1.4B
$98.1M 23.22%
7,648,268
– –
ITOS
2
DELISTED
iTeos Therapeutics
ITOS
$33.3M 7.88%
1,745,943
– –
INBX
3
DELISTED
Inhibrx, Inc. Common Stock
INBX
$23M 5.44%
1,279,995
+256,670
+25% +$4.63M
VERV
4
DELISTED
Verve Therapeutics
VERV
$21.8M 5.17%
+635,792
New +$20.3M
NTLA icon
5
Intellia Therapeutics
NTLA
$1.8B
$21M 4.96%
374,409
+75,000
+25% +$4.65M
RPTX
6
DELISTED
Repare Therapeutics
RPTX
$19.9M 4.71%
1,639,849
– –
GERN icon
7
Geron
GERN
$970M
$19.7M 4.67%
8,422,582
-12,409
-0.1% -$27.8K
ISEE
8
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$18.8M 4.46%
+1,050,000
New +$13.8M
MRUS
9
DELISTED
Merus
MRUS
$18.4M 4.36%
918,310
-1,172
-0.1% -$28K
RGNX icon
10
Regenxbio
RGNX
$638M
$16.4M 3.88%
+619,083
New +$18.4M
IOVA icon
11
Iovance Biotherapeutics
IOVA
$3.63B
$16.3M 3.86%
1,700,000
+500,000
+42% +$5.77M
HOWL icon
12
Werewolf Therapeutics
HOWL
$45.8M
$10.8M 2.55%
2,388,011
– –
GTHX
13
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$10.7M 2.53%
856,798
– –
CYTK icon
14
Cytokinetics
CYTK
$10B
$9.36M 2.22%
193,205
-1,041
-0.5% -$50.1K
BCRX icon
15
BioCryst Pharmaceuticals
BCRX
$2.51B
$7.63M 1.81%
605,663
-33,426
-5% -$430K
CRNX icon
16
Crinetics Pharmaceuticals
CRNX
$9B
$7.16M 1.7%
364,710
-1,966
-0.5% -$40.1K
TVTX icon
17
Travere Therapeutics
TVTX
$6.19B
$6.81M 1.61%
276,460
-1,490
-0.5% -$38.5K
YMAB
18
DELISTED
Y-mAbs Therapeutics
YMAB
$6.4M 1.52%
443,702
– –
TCRR
19
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
$6.07M 1.44%
3,370,982
– –
HRMY icon
20
Harmony Biosciences
HRMY
$2.28B
$6.06M 1.43%
136,780
-737
-0.5% -$36K
ARQT icon
21
Arcutis Biotherapeutics
ARQT
$2.99B
$4.92M 1.16%
257,185
-1,315
-0.5% -$29.8K
RETA
22
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$4.5M 1.07%
179,058
-942
-0.5% -$26.1K
FOLD
23
DELISTED
Amicus Therapeutics
FOLD
$4.1M 0.97%
392,946
-102,657
-21% -$1.14M
PRVB
24
DELISTED
Provention Bio, Inc. Common Stock
PRVB
$3.33M 0.79%
740,344
+147,909
+25% +$674K
HARP
25
DELISTED
Harpoon Therapeutics, Inc. Common Stock
HARP
$3.1M 0.73%
319,671
– –
1
2

Similar funds

OCM
Opti Capital Management New York $1.64B AUM 0% 1-Year Est. Return
LFS
Lutz Financial Services Omaha, Nebraska $1.64B AUM 15.04% 1-Year Est. Return
TIM
Triodos Investment Management Driebergen-Rijsenburg, Netherlands $1.64B AUM 37.98% 1-Year Est. Return
AAG
Armstrong Advisory Group Needham, Massachusetts $1.64B AUM 19.37% 1-Year Est. Return
MRG
Milestone Resources Group Road Town Tortola, British Virgin Islands $1.64B AUM 2.87% 1-Year Est. Return
EPW
Evolve Private Wealth Los Angeles, California $1.64B AUM
TWM
Tradition Wealth Management Edina, Minnesota $1.64B AUM 26.59% 1-Year Est. Return
MA
MONECO Advisors Fairfield, Connecticut $1.64B AUM 25.43% 1-Year Est. Return

MPM BioImpact's Q3 2022 Portfolio in Review

As of Q3 2022, MPM BioImpact held 41 positions worth $422M, up 17% from $360M the previous quarter. Its ten largest holdings account for 69% of the portfolio.

MPM BioImpact deployed $55.4M of net new capital in Q3 2022, opening 4 new positions and adding to 4 existing holdings. Its largest new stake was Verve Therapeutics: 635,792 shares worth $21.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Mirum Pharmaceuticals, an estimated $4.6M trimmed.

  • MPM BioImpact's largest Q3 2022 buy was Verve Therapeutics: 635,792 shares worth $21.8M.
  • MPM BioImpact added most to Iovance Biotherapeutics in Q3 2022, an estimated $5.77M increase.
  • MPM BioImpact's biggest Q3 2022 reduction was Mirum Pharmaceuticals, cutting an estimated $4.6M.
  • MPM BioImpact fully exited Epizyme, Inc in Q3 2022, selling an estimated $5.04M.
  • MPM BioImpact's ten largest holdings make up 69% of its $422M portfolio in Q3 2022.
  • MPM BioImpact opened 4 new positions and closed 3 in Q3 2022.
  • MPM BioImpact's portfolio value rose 17% quarter-over-quarter to $422M.

Based on MPM BioImpact's 13F filing for Q3 2022, filed 14 Nov 2022.